GlassScriptPhysician profile
Wallace W Mclean
NPI 1689774390
$978.64
in general payments reported to CMS, 2019-2025
21 companies · $166 in 2025
The $166 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.65 · 2020: $51.33 · 2021: $167 · 2022: $224 · 2023: $220 · 2024: $74.87 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $460.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $247.79 | 2020-2025 | Slynd |
| Pfizer INC. | $139.63 | 2021-2025 | |
| Intuitive Surgical, INC. | $81.57 | 2023 | Da Vinci Surgical System |
| Merck Sharp & Dohme LLC | $72.05 | 2021-2023 | Gardasil 9 |
| Abbvie INC. | $56.25 | 2021-2022 | |
| Organon LLC | $39.92 | 2022-2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $39.90 | 2025 | |
| Evofem Biosciences, INC. | $38.92 | 2021-2022 | |
| Therapeuticsmd, INC. | $33.81 | 2019-2020 | |
| Hologic Sales and Service, LLC | $29.08 | 2019 | |
| Mylan Pharmaceuticals INC. | $29.06 | 2022 | |
| Covidien LP | $24.35 | 2019 | |
| Renovia INC | $23.72 | 2021 | |
| Novo Nordisk INC | $21.48 | 2023 | Wegovy |
| Amgen INC. | $20.66 | 2024 | Evenity, Prolia |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $20.65 | 2021 | |
| Aspira Women'S Health INC | $16.38 | 2020 | |
| Millicent US INC | $14.73 | 2025 | Femring, Intrarosa |
| Shield Therapeutics INC | $14.41 | 2023 | Accrufer |
| Mayne Pharma Commercial LLC | $14.28 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wallace Mclean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.